ReviewCardiovascular diagnosis and therapy2025
Recent clinical research on the value of high-sensitivity cardiac troponin levels in prognostic evaluation after coronary artery bypass graft surgery: a narrative review.
Review in Cardiovascular diagnosis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in basic research on post-cardiac arrest syndrome in adults: a comprehensive review.Frontiers in medicine · 2026Review
- High Troponin I in Patients Following Off-pump Coronary Artery Bypass Grafting.Cardiac failure review · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Coronary artery bypass grafting (CABG) is an effective treatment for coronary artery disease, high risk of complications, making it particularly important to assess patient prognosis. High-sensitivity cardiac troponin (hs-cTn), as a key biomarker of myocardial injury, plays an important role in evaluating the prognosis of patients after CABG. However, the optimal threshold values for hs-cTn in the current guidelines are all artificially set, lacking a unified standard. This narrative review aims to fill the knowledge gap and provide new directions for future research. This is of significant importance for optimizing the management of patients after CABG, improving prognosis, and for developing more precise and personalized treatment strategies. Methods: We conducted a structured search on PubMed, Web of Science MEDLINE and Cochrane Library using terms like "High-Sensitivity Cardiac Troponin", "Coronary Artery Bypass Grafting", "Prognosis", "Mortality", and "Postoperative Outcomes" to identify English-language studies from inception to 25 July 2024. This article systematically reviews recent studies on hs-cTn levels and prognostic risk factors after CABG, aiming to comprehensively sort out and analyze existing research findings. Key Content and Findings: Studies show that the release of hs-cTnT and hs-cTnI is related to postoperative myocardial injury/infarction and short-term mortality, but there is still controversy in the conclusions regarding long-term mortality. In addition, different studies have drawn different conclusions about the application of hs-cTnI in postoperative myocardial infarction, restenosis, and hypoxemia, as well as its association with mortality. However, a common view is that the hs-cTn cutoff values used in current clinical practice are too conservative, which may limit the accuracy of its prognosis assessment. Conclusions: Hs-cTn has significant value in the prognosis assessment of patients after CABG, but its clinical decision level often exceeds the critical values specified in the guidelines. In the future, more rigorous prospective multicenter trials need to be conducted in different populations to further determine the optimal diagnostic thresholds for hs-cTn, thereby improving the accuracy of prognosis assessment in patients after CABG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.